Nyxoah to Report Third Quarter Financial Results
Nyxoah is gearing up to unveil its financial results for the third quarter of 2025, a moment that signifies its ongoing commitment to transforming the treatment landscape for Obstructive Sleep Apnea (OSA). The announcement is set to take place on November 13, 2025, followed by a comprehensive conference call where company leadership will delve into the results and future strategies.
Understanding Nyxoah's Innovations
Nyxoah, with its innovative focus on OSA treatment, has been making significant strides in developing pioneering solutions. The company’s flagship product, the Genio system, utilizes a unique approach through hypoglossal neurostimulation therapy, aiming to alleviate the challenges faced by OSA patients. With OSA being a prevalent sleep disorder linked to serious health risks such as cardiovascular conditions, Nyxoah's mission resonates deeply within the healthcare community.
The Upcoming Earnings Call
On November 13, the conference call is scheduled to begin at 10:30 PM CET / 4:30 PM ET. For those keen on engaging with management, it's recommended to register in advance to secure a spot. An archived version of the webcast will be available post-event, ensuring that stakeholders won’t miss out on any critical insights.
Company's Achievements and Future Goals
Nyxoah has made notable progress, having received the European CE mark for the Genio system in 2019, alongside successful public offerings on Euronext Brussels and Nasdaq. These milestones reflect Nyxoah's strong trajectory towards growth and market presence. The recent positive outcomes from the BETTER SLEEP study have expanded the indications for their therapy, which sets them apart from traditional competitors.
The Heart of Nyxoah's Vision
Nyxoah envisions a world where OSA patients can experience uninterrupted sleep and lead fulfilling lives. This vision drives their innovative research and product development. The Genio system has been recognized as a groundbreaking, patient-centered solution that stands out due to its leadless and battery-free design—essential features that enhance patient comfort and usability.
Continuing to Innovate in Sleep Health
The commitment to ongoing research is evident in Nyxoah’s ambitious clinical studies, including the DREAM IDE pivotal study. With FDA approval for a Premarket Approval application obtained recently, the excitement around Nyxoah continues to build. This expansion of their therapeutic options is set to further advance their impact in the field, providing hope to many suffering from OSA.
Investor Relations and Contact Information
Nyxoah’s leadership acknowledges the importance of transparent communication with stakeholders. Interested individuals can reach out to Rémi Renard, Chief Investor Relations and Corporate Communication Officer, at IR@nyxoah.com. The company's investor relations page holds the key to additional insights and updates regarding their initiatives.
Frequently Asked Questions
What is the date for Nyxoah's Q3 2025 financial results release?
Nyxoah is set to release its financial results on November 13, 2025.
How can I listen to the earnings call?
You can access the earnings call via the Nyxoah Investor Relations page or through registration provided by the Company.
What is the Genio system?
The Genio system is a hypoglossal neurostimulation therapy developed by Nyxoah for the treatment of Obstructive Sleep Apnea.
What recent approvals has Nyxoah achieved?
Nyxoah recently received FDA approval for its Premarket Approval application and has expanded its therapeutic indications following successful clinical trials.
Who can I contact for more investor-related queries?
For inquiries, contact Rémi Renard at IR@nyxoah.com for investor relations support.
